ClinicalTrials.gg
CompletedNCT04751487AERIFY-2Updated Oct 9, 2026Results posted

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Itepekimab SAR440340 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 238 sites in 29 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Oct 9, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,234
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Enrollment
2nd of 12
1,234 · median 937
Started
2021
with 1 other
Phase 3
8 of 15
3 open now
Registered
5th of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 5th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

Primary population (former smokers cohort):

- Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD

Secondary Objectives:

Primary population (former smokers cohort):

  • Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD
  • Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD
  • Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD
  • Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD

Secondary population (current smokers cohort)

  • Estimate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate or severe COPD exacerbations in current smokers with moderate-to-severe COPD
  • Estimate the efficacy of itepekimab compared with placebo on pulmonary function in current smokers with moderate-to-severe COPD
  • Estimate the safety and tolerability of itepekimab in current smokers with moderate-to-severe COPD
  • Estimate the PK profile of itepekimab in current smokers with moderate to severe COPD
  • Estimate immunogenicity to itepekimab in current smokers with moderate-to-severe COPD
Read the detailed description

The study duration per participant:

  • Screening period was 3-5 weeks
  • Randomized investigational medicinal product (IMP) treatment period was 52 weeks for first cohort of randomized former smoker participants [approximately 930] and cohort of current smokers [approximately 280], and 24 to 52 weeks for potential additional randomized former smoker participants
  • Post-IMP treatment follow-up period was 20 weeks for participants not transitioning to the extension study LTS18133 (NCT06208306)

Note: A long-term, double-blinded extension study would be implemented to allow participants in this study to continue receiving active IMP for an additional period. Only participants completing their End-of-Treatment (EOT) visit per this study protocol would be offered to participate in the LTS18133 study (NCT06208306).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 40 to 85 years of age inclusive.
  • Physician diagnosis of for at least 1 year (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition).
  • Smoking history of ≥10 pack-years:

    • For former smokers: participants who reported that they were not currently smoking and smoking cessation must had occurred ≥6 months prior to Screening (Visit 1A) with an intention to quit permanently.
    • For current smokers: participants who reported that they were currently smoking tobacco (participant smoked at least 1 cigarette per day on average during the past 7 days) at Screening (Visit 1A) and who were not currently participating in or planning to initiate a smoking cessation intervention at Screening (Visit 1A) or during Screening period.
  • Participants with moderate-to-severe COPD
  • Participant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year prior to Screening in a participant in whom other causes of chronic cough [eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis] had been excluded).
  • Documented history of high exacerbation risk defined as having had ≥2 moderate or ≥1 severe exacerbations within the year prior to Screening (Visit 1A), with at least 1 exacerbation treated with systemic . At least one exacerbation must had occurred while participants were on their current controller therapy:

    • Moderate exacerbations would be recorded by the Investigator and were defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics.
    • Severe exacerbations would be recorded by the Investigator and were defined as AECOPD that required hospitalization or observation for >24 hours in emergency department/urgent care facility.
  • Participants with standard of care controller therapy, for ≥3 months prior to Screening (Visit 1A) and at a stable dose of controller therapy for at least 1 month prior to the Screening, including either: inhaled corticosteroid (ICS) + long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA) + LABA or LAMA + LABA + ICS.
  • (BMI) ≥18.0 kg/m\^2, or BMI ≥16.0 kg/m\^2 for participants enrolled in East-Asian countries.
  • Female participant was not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • not a women of (WOCBP) OR
    • a WOCBP who agreed to follow the guidance during the intervention period and for at least 20 weeks after the last dose of study intervention. -

Exclusion criteria

Exclusion criteria:

  • Current diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines, or documented history of asthma unless asthma resolved before 18 years of age and has not recurred.
  • For former smokers: Active smoking or vaping of any products (eg, nicotine, tetrahydrocannabinol [THC]) within 6 months prior to Screening (Visit 1A).
  • For current smokers: vaping of any products (eg, nicotine, THC) within 6 months prior to Screening (Visit 1A).
  • new abnormal (ECG) within 6 months prior to, or at Screening (Visit 1A) that might affect the participant's participation in the study.
  • Clinically significant and current pulmonary disease other than , eg, sarcoidosis, interstitial lung disease, bronchiectasis (clinical diagnosis), diagnosis of α-1 anti-trypsin deficiency, or another diagnosed pulmonary disease.
  • Diagnosis of cor pulmonale, evidence of right cardiac failure, or moderate-to-severe pulmonary hypertension.
  • Hypercapnia requiring bilevel positive airway pressure (BiPAP).
  • Moderate or severe exacerbation of COPD (AECOPD) within 4 weeks prior to Screening (Visit 1A).
  • Prior history of / planned: lung pneumonectomy for any reason, or lung volume reduction procedures (including bronchoscopic volume reduction) for COPD. Note: Surgical , or segmentectomy, or wedge resection, or lobectomy for other diseases would not be excluded.
  • Unstable ischemic heart disease, including acute myocardial infarction within the past 1 year prior to Screening, or unstable angina in the 6 months prior to Screening (Visit 1A).
  • Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation.
  • Uncontrolled hypertension (ie, systolic blood pressure [BP] >180 mm Hg or diastolic BP >110 mm Hg with or without use of anti-hypertensive therapy).
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who were at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1A).
  • History of (HIV) infection or positive HIV 1/2 serology at Screening (Visit 1A).
  • Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in contact with known exposure to COVID-19 at Screening (Visit 1A); known history of COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to Screening (Visit 1A); participants who have had a COVID-19 infection prior Screening (Visit 1A) who had not yet sufficiently recovered to participate in the procedures of a clinical trial.
  • Evidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4 weeks before Screening (Visit 1A), significant viral infections within 4 weeks before Screening (Visit 1A) that might not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment).
  • Participants with active disease or participants using therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis.
  • History of within 5 years before Screening (Visit 1A), except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
  • Previous use of itepekimab.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,234 participants (actual)

Study arms

  • Experimental
    Itepekimab Q2W in former smokers

    Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks

    Drug: Itepekimab SAR440340

  • Experimental
    Itepekimab Q4W in former smokers

    SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP

    Drug: Itepekimab SAR440340 · Drug: Placebo

  • Placebo comparator
    Placebo in former smokers

    SC administration of matching placebo Q2W for up to 52 weeks

    Drug: Placebo

  • Experimental
    Itepekimab Q2W in current smokers

    SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks

    Drug: Itepekimab SAR440340

  • Placebo comparator
    Placebo in current smokers

    SC administration of matching placebo Q2W for 52 weeks

    Drug: Placebo

Interventions

  • Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

    Also known as: REGN3500

  • DrugPlacebo

    Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Former Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the 52-Week Placebo-Controlled Treatment Period

    Exacerbations were recorded by Investigator. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (such as intramuscular \[IM\], intravenous \[IV\], or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of systemic steroids/antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate was total number of moderate or severe exacerbation events divided by total observation duration and was estimated based on negative binomial regression. Events were adjudicated by third party.

    Time frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants

Secondary outcomes

  1. Former Smoker Cohort: Annualized Rate of Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Planned Treatment Period

    Exacerbations were recorded by the Investigator. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. Annualized rate was the total number of severe exacerbation events divided by the total observation duration and was estimated based on negative binomial regression. Events were adjudicated by third party.

    Time frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants

  2. Former Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 24

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 24 is presented.

    Time frame: Baseline (Day 1) to Week 24

  3. Former Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) Total Score at Week 24

    E-RS:COPD scale was patient-reported outcome (PRO) and derivative of Exacerbations of Chronic pulmonary Disease Tool (EXACT) tool. It comprised of 11 respiratory symptom items contained in 14-item of EXACT instrument: breathlessness (2 items scored from 0-4 and 3 items scored from 0-3); cough and sputum (2 items scored from 0-4 and 1 item scored from 0-3); chest symptoms (3 items scored from 0-4); difficulty bringing up sputum; tired or weak; sleep disturbance and scared or worried (each contained 1 item scored from 0-3). Total score was the sum of scores for 11 items comprising instrument and ranged from 0 to 40; higher values indicated more severe respiratory symptoms. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 24 is presented.

    Time frame: Baseline (Day 1) to Week 24

  4. Former Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 24

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of short-acting beta-agonist (SABA; albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 24 is presented.

    Time frame: Baseline (Day 1) to Week 24

  5. Former Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24

    SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 24 is presented.

    Time frame: Baseline (Day 1) to Week 24

  6. Former Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 24

    SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as last available value collected prior to first study treatment administration. Percentages are rounded off to tenth decimal place.

    Time frame: Baseline (Day 1) and Week 24

  7. Former Smoker Cohort: Rate of Change in Post-Bronchodilator Forced Expiratory Volume in One Second From Baseline (Post-Bronchodilator Forced Expiratory Volume in One Second Slope) After Week 4

    The rate of change from baseline in post-BD FEV1 (or post-BD FEV1 slope) after a period of initial BD effect (after Week 4) were estimated to assess the rate of decline in lung function over time, commonly observed in participants with inadequately controlled COPD. The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of SABA (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as last available value collected prior to first study treatment administration.

    Time frame: Baseline (Day 1) and from Week 8 up to Week 52 for initial randomized participants; Baseline (Day 1) and from Week 8 up to a variable study treatment period (i.e., 24 weeks minimum and 52 weeks maximum) for additional randomized participants

  8. Former Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 52

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of SABA (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 52 is presented.

    Time frame: Baseline (Day 1) to Week 52

  9. Former Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 52

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a wash out period of BD according to their action duration. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 52 is presented.

    Time frame: Baseline (Day 1) to Week 52

  10. Former Smoker Cohort: Probability of Participants With First Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment Period

    Exacerbations were recorded by Investigator. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (such as IM, IV, or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. Probability of participants with first adjudicated moderate or severe AECOPD in Weeks 12, 24, 36, and 52 was based on Kaplan-Meier estimates. Events were adjudicated by third party.

    Time frame: Baseline (Day 1) up to Weeks 12, 24, 36 and 52

  11. Former Smoker Cohort: Probability of Participants With First Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment Period

    Exacerbations were recorded by Investigator. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. Probability of participants with first adjudicated severe AECOPD in Weeks 12, 24, 36, and 52 was based on Kaplan-Meier estimates. Events were adjudicated by third party.

    Time frame: Baseline (Day 1) up to Weeks 12, 24, 36 and 52

  12. Former Smoker Cohort: Annualized Rate of Corticosteroid-Treated Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Placebo-Controlled Treatment Period

    Exacerbations were recorded by Investigator. Moderate/severe AECOPD events which were treated with regimen containing systemic corticosteroids for AECOPD; at time of AECOPD were considered. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (IM, IV, or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in emergency department/urgent care facility or resulted in death. For moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of systemic steroids/antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events). Annualized rate: total number of corticosteroid-treated AECOPD events divided by total observation duration and was estimated based on negative binomial regression.

    Time frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants

  13. Former Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease Total Score at Week 52

    E-RS:COPD scale was PRO and derivative of EXACT tool. It comprised of 11 respiratory symptom items contained in 14-item of EXACT instrument: breathlessness (2 items scored from 0-4 and 3 items scored from 0-3); cough and sputum (2 items scored from 0-4 and 1 item scored from 0-3); chest symptoms (3 items scored from 0-4); difficulty bringing up sputum; tired or weak; sleep disturbance and scared or worried (each contained 1 item scored from 0-3). Total score was the sum of scores for 11 items comprising instrument and ranged from 0 to 40; higher values indicated more severe respiratory symptoms. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 52 is presented.

    Time frame: Baseline (Day 1) to Week 52

  14. Former Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52

    SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 52 is presented.

    Time frame: Baseline (Day 1) to Week 52

  15. Former Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52

    SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as the last available value collected prior to first study treatment administration. Percentages are rounded off to tenth decimal place.

    Time frame: Baseline (Day 1) and Week 52

  16. Former Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), TE Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Permanent Treatment Discontinuation

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent period.

    Time frame: 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)

  17. Former Smoker Cohort: Functional Itepekimab Concentrations in Serum

    Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

    Time frame: Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (End of study [EOS]) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)

  18. Former Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response

    Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the anti-drug antibody (ADA) assay post first dose when baseline results were negative or missing.

    Time frame: 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)

  19. Current Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over the 52-Week Placebo-Controlled Treatment Period

    Exacerbations were recorded by Investigator. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (such as IM, IV, or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of systemic steroids/antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate was the total number of moderate or severe exacerbation events divided by the total observation duration and was estimated based on negative binomial regression. Events were adjudicated by third party.

    Time frame: Baseline (Day 1) up to Week 52

  20. Current Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Weeks 24 and 52

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Weeks 24 and 52 are presented.

    Time frame: Baseline (Day 1) and Weeks 24 and 52

  21. Current Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events, Treatment-Emergent Adverse Events of Special Interest and TEAEs Leading to Permanent Treatment Discontinuation

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent period.

    Time frame: 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)

  22. Current Smoker Cohort: Functional Itepekimab Concentrations in Serum

    Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

    Time frame: Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (EOS) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)

  23. Current Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response

    Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing.

    Time frame: 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)

07

Results

Posted Oct 9, 2026

Participant flow

Study was conducted at 279 centers in 29 countries. 2512 participants were screened from 12-Feb-2021 to 15-May-2024, of which 1273 were screen failures due to not meeting eligibility criteria. 1239 participants were randomized, of which 5 were excluded due to GCP non-compliances, thus 1234 were analyzed: 953 in Former smoker cohort (1:1:1 ratio into 3 arms) and 281 in Current smoker cohort (1:1 ratio into 2 arms).

Participant flow — Overall Study
MilestoneFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2WCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
Started324303326139142
Completed276256281124112
Not completed4847451530
Withdrew: Adverse event17181578
Withdrew: Progressive disease10000
Withdrew: Poor compliance to protocol01101
Withdrew: Withdrawal by subject242425820
Withdrew: Other-not related to coronavirus disease-201933301
Withdrew: Randomized, not exposed31100

Outcome measures

SecondaryFormer Smoker Cohort: Annualized Rate of Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Planned Treatment Period

Exacerbations were recorded by the Investigator. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. Annualized rate was the total number of severe exacerbation events divided by the total observation duration and was estimated based on negative binomial regression. Events were adjudicated by third party.

Time frame:
Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
Reported as:
Number · exacerbation per participant-year
Former Smoker Cohort: Annualized Rate of Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Planned Treatment Period
exacerbation per participant-yearFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Annualized Rate of Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Planned Treatment Period0.105 ± 0.0660.096 ± 0.0590.113 ± 0.072
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · Negative binomial regression model · p = = 0.7315 · Rate ratio: 0.914 · 95% CI 0.548 to 1.526
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · Negative binomial regression model · p = = 0.7753 · Rate ratio: 1.075 · 95% CI 0.653 to 1.769
SecondaryFormer Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 24

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 24 is presented.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Least squares mean · liters
Former Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 24
litersFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 24-0.006 ± 0.0140.069 ± 0.0140.032 ± 0.014
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · MMRM · p = < 0.0001 · Least squares (ls) mean difference: 0.075 · 95% CI 0.039 to 0.110
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · MMRM · p = = 0.0311 · Ls mean difference: 0.038 · 95% CI 0.003 to 0.073
SecondaryFormer Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) Total Score at Week 24

E-RS:COPD scale was patient-reported outcome (PRO) and derivative of Exacerbations of Chronic pulmonary Disease Tool (EXACT) tool. It comprised of 11 respiratory symptom items contained in 14-item of EXACT instrument: breathlessness (2 items scored from 0-4 and 3 items scored from 0-3); cough and sputum (2 items scored from 0-4 and 1 item scored from 0-3); chest symptoms (3 items scored from 0-4); difficulty bringing up sputum; tired or weak; sleep disturbance and scared or worried (each contained 1 item scored from 0-3). Total score was the sum of scores for 11 items comprising instrument and ranged from 0 to 40; higher values indicated more severe respiratory symptoms. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 24 is presented.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Least squares mean · score on a scale
Former Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) Total Score at Week 24
score on a scaleFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) Total Score at Week 24-1.471 ± 0.313-2.039 ± 0.319-1.457 ± 0.309
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · MMRM · p = = 0.1785 · Ls mean difference: -0.568 · 95% CI -1.396 to 0.260
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · MMRM · p = = 0.9734 · Ls mean difference: 0.014 · 95% CI -0.802 to 0.830
SecondaryFormer Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 24

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of short-acting beta-agonist (SABA; albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 24 is presented.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Least squares mean · liters
Former Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 24
litersFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 240.003 ± 0.0130.071 ± 0.0140.018 ± 0.013
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · MMRM · p = = 0.0001 · Ls mean difference: 0.068 · 95% CI 0.034 to 0.102
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · MMRM · p = = 0.4057 · Ls mean difference: 0.014 · 95% CI -0.019 to 0.048
SecondaryFormer Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24

SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 24 is presented.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Least squares mean · score on a scale
Former Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24
score on a scaleFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24-6.834 ± 0.965-8.328 ± 0.978-7.960 ± 0.958
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · MMRM · p = = 0.2221 · Ls mean difference: -1.493 · 95% CI -3.893 to 0.906
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · MMRM · p = = 0.3525 · Ls mean difference: -1.126 · 95% CI -3.502 to 1.250
SecondaryFormer Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 24

SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. Scores by dimension were calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as last available value collected prior to first study treatment administration. Percentages are rounded off to tenth decimal place.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · percentage of participants
Former Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 24
percentage of participantsFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 2441.746.541.1
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · Regression, Logistic · p = = 0.2351 · Odds ratio (or): 1.225 · 95% CI 0.876 to 1.712
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · Regression, Logistic · p = = 0.6570 · Odds ratio (or): 0.928 · 95% CI 0.667 to 1.291
SecondaryFormer Smoker Cohort: Rate of Change in Post-Bronchodilator Forced Expiratory Volume in One Second From Baseline (Post-Bronchodilator Forced Expiratory Volume in One Second Slope) After Week 4

The rate of change from baseline in post-BD FEV1 (or post-BD FEV1 slope) after a period of initial BD effect (after Week 4) were estimated to assess the rate of decline in lung function over time, commonly observed in participants with inadequately controlled COPD. The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of SABA (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as last available value collected prior to first study treatment administration.

Time frame:
Baseline (Day 1) and from Week 8 up to Week 52 for initial randomized participants; Baseline (Day 1) and from Week 8 up to a variable study treatment period (i.e., 24 weeks minimum and 52 weeks maximum) for additional randomized participants
Reported as:
Least squares mean · liters per year
Former Smoker Cohort: Rate of Change in Post-Bronchodilator Forced Expiratory Volume in One Second From Baseline (Post-Bronchodilator Forced Expiratory Volume in One Second Slope) After Week 4
liters per yearFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Rate of Change in Post-Bronchodilator Forced Expiratory Volume in One Second From Baseline (Post-Bronchodilator Forced Expiratory Volume in One Second Slope) After Week 4-0.028 ± 0.027-0.014 ± 0.027-0.030 ± 0.027
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · MMRM · p = = 0.4621 · Ls mean difference: 0.014 · 95% CI -0.024 to 0.053
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · MMRM · p = = 0.9131 · Ls mean difference: -0.002 · 95% CI -0.039 to 0.035
SecondaryFormer Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 52

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of SABA (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 52 is presented.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · liters
Former Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 52
litersFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 52-0.003 ± 0.0150.053 ± 0.015-0.007 ± 0.015
SecondaryFormer Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 52

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a wash out period of BD according to their action duration. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Week 52 is presented.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · liters
Former Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 52
litersFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 52-0.011 ± 0.0150.053 ± 0.0160.014 ± 0.015
SecondaryFormer Smoker Cohort: Probability of Participants With First Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment Period

Exacerbations were recorded by Investigator. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (such as IM, IV, or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. Probability of participants with first adjudicated moderate or severe AECOPD in Weeks 12, 24, 36, and 52 was based on Kaplan-Meier estimates. Events were adjudicated by third party.

Time frame:
Baseline (Day 1) up to Weeks 12, 24, 36 and 52
Reported as:
Number · probability of participants
Former Smoker Cohort: Probability of Participants With First Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment Period
probability of participantsFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Week 120.244 ± 0.1990.194 ± 0.1510.183 ± 0.143
Week 240.375 ± 0.3220.317 ± 0.2640.321 ± 0.271
Week 360.462 ± 0.4060.421 ± 0.3640.446 ± 0.391
Week 520.539 ± 0.4820.508 ± 0.4480.537 ± 0.479
SecondaryFormer Smoker Cohort: Probability of Participants With First Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment Period

Exacerbations were recorded by Investigator. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. Probability of participants with first adjudicated severe AECOPD in Weeks 12, 24, 36, and 52 was based on Kaplan-Meier estimates. Events were adjudicated by third party.

Time frame:
Baseline (Day 1) up to Weeks 12, 24, 36 and 52
Reported as:
Number · probability of participants
Former Smoker Cohort: Probability of Participants With First Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment Period
probability of participantsFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Week 120.031 ± 0.0160.020 ± 0.0080.015 ± 0.006
Week 240.064 ± 0.0400.044 ± 0.0250.050 ± 0.030
Week 360.080 ± 0.0530.079 ± 0.0520.076 ± 0.050
Week 520.107 ± 0.0760.108 ± 0.0750.112 ± 0.080
SecondaryFormer Smoker Cohort: Annualized Rate of Corticosteroid-Treated Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Placebo-Controlled Treatment Period

Exacerbations were recorded by Investigator. Moderate/severe AECOPD events which were treated with regimen containing systemic corticosteroids for AECOPD; at time of AECOPD were considered. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (IM, IV, or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in emergency department/urgent care facility or resulted in death. For moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of systemic steroids/antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events). Annualized rate: total number of corticosteroid-treated AECOPD events divided by total observation duration and was estimated based on negative binomial regression.

Time frame:
Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
Reported as:
Number · exacerbation per participant-year
Former Smoker Cohort: Annualized Rate of Corticosteroid-Treated Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Placebo-Controlled Treatment Period
exacerbation per participant-yearFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Annualized Rate of Corticosteroid-Treated Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Placebo-Controlled Treatment Period0.804 ± 0.6600.631 ± 0.5110.722 ± 0.592
SecondaryFormer Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease Total Score at Week 52

E-RS:COPD scale was PRO and derivative of EXACT tool. It comprised of 11 respiratory symptom items contained in 14-item of EXACT instrument: breathlessness (2 items scored from 0-4 and 3 items scored from 0-3); cough and sputum (2 items scored from 0-4 and 1 item scored from 0-3); chest symptoms (3 items scored from 0-4); difficulty bringing up sputum; tired or weak; sleep disturbance and scared or worried (each contained 1 item scored from 0-3). Total score was the sum of scores for 11 items comprising instrument and ranged from 0 to 40; higher values indicated more severe respiratory symptoms. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 52 is presented.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · score on a scale
Former Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease Total Score at Week 52
score on a scaleFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease Total Score at Week 52-1.348 ± 0.340-2.075 ± 0.352-1.757 ± 0.338
SecondaryFormer Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52

SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as the last available value collected prior to first study treatment administration. Model-based average change from baseline to Week 52 is presented.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · score on a scale
Former Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52
score on a scaleFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52-7.573 ± 1.062-7.730 ± 1.096-8.240 ± 1.054
SecondaryFormer Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52

SGRQ had 2 parts: part 1 consisted of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consisted of 42 items related to the daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension calculated for 3 domains: symptoms, activity and impacts (psychosocial) which ranged from 0 to 100; higher scores indicated greater impairment. Total score was calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire and ranged from 0 (best possible health status) to 100 (worst possible health status); lower scores indicated better health status. Baseline was defined as the last available value collected prior to first study treatment administration. Percentages are rounded off to tenth decimal place.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Number · percentage of participants
Former Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52
percentage of participantsFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 5242.043.540.6
SecondaryFormer Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), TE Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Permanent Treatment Discontinuation

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent period.

Time frame:
1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)
Reported as:
Count of participants · Participants
Former Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), TE Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Permanent Treatment Discontinuation
ParticipantsFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
TEAEs206215209
TESAEs727474
TEAESIs374451
TEAE: Led to permanent treatment discontinuation171814
SecondaryFormer Smoker Cohort: Functional Itepekimab Concentrations in Serum

Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

Time frame:
Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (End of study [EOS]) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)
Reported as:
Mean · nanograms per milliliter
Former Smoker Cohort: Functional Itepekimab Concentrations in Serum
nanograms per milliliterFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Baseline (Day 1)17.25 ± 287.9374.01 ± 1115.01
Week 219114.10 ± 7290.7918215.19 ± 6778.96
Week 413174.67 ± 5253.4830554.88 ± 12347.71
Week 819429.82 ± 8261.8244800.05 ± 18014.69
Week 1222751.72 ± 10267.1452445.58 ± 22798.25
Week 2424447.04 ± 11802.8858487.49 ± 27554.69
Week 3624762.77 ± 12749.4458866.33 ± 29007.26
Week 5226369.87 ± 13530.2460851.12 ± 28449.87
Week 587975.17 ± 5247.8020354.39 ± 13082.21
Week 721006.46 ± 2150.921902.15 ± 2081.18
SecondaryFormer Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response

Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the anti-drug antibody (ADA) assay post first dose when baseline results were negative or missing.

Time frame:
1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)
Reported as:
Count of participants · Participants
Former Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response
ParticipantsFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response1075
SecondaryCurrent Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over the 52-Week Placebo-Controlled Treatment Period

Exacerbations were recorded by Investigator. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (such as IM, IV, or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of systemic steroids/antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate was the total number of moderate or severe exacerbation events divided by the total observation duration and was estimated based on negative binomial regression. Events were adjudicated by third party.

Time frame:
Baseline (Day 1) up to Week 52
Reported as:
Number · exacerbation per participant-year
Current Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over the 52-Week Placebo-Controlled Treatment Period
exacerbation per participant-yearCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
Current Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over the 52-Week Placebo-Controlled Treatment Period0.704 ± 0.4650.654 ± 0.431
SecondaryCurrent Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Weeks 24 and 52

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration. Baseline was defined as the last available value collected prior to the first study treatment administration. Model-based average change from baseline to Weeks 24 and 52 are presented.

Time frame:
Baseline (Day 1) and Weeks 24 and 52
Reported as:
Least squares mean · liters
Current Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Weeks 24 and 52
litersCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
Week 240.006 ± 0.028-0.023 ± 0.027
Week 52-0.025 ± 0.029-0.041 ± 0.028
SecondaryCurrent Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events, Treatment-Emergent Adverse Events of Special Interest and TEAEs Leading to Permanent Treatment Discontinuation

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent period.

Time frame:
1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)
Reported as:
Count of participants · Participants
Current Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events, Treatment-Emergent Adverse Events of Special Interest and TEAEs Leading to Permanent Treatment Discontinuation
ParticipantsCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
TEAEs9290
TESAEs2836
TEAESIs1318
TEAE: Led to permanent treatment discontinuation78
SecondaryCurrent Smoker Cohort: Functional Itepekimab Concentrations in Serum

Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

Time frame:
Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (EOS) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)
Reported as:
Mean · nanograms per milliliter
Current Smoker Cohort: Functional Itepekimab Concentrations in Serum
nanograms per milliliterCurrent Smoker Cohort: Itepekimab 300 mg Q2W
Baseline (Day 1)0.00 ± 0.00
Week 216935.88 ± 5860.48
Week 428944.22 ± 11175.70
Week 840781.94 ± 16864.62
Week 1248132.08 ± 23197.56
Week 2450966.38 ± 27248.27
Week 3651175.00 ± 26068.36
Week 5252496.33 ± 26295.06
Week 5817294.59 ± 11481.66
Week 721607.92 ± 1430.69
SecondaryCurrent Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response

Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing.

Time frame:
1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)
Reported as:
Count of participants · Participants
Current Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response
ParticipantsCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
Current Smoker Cohort: Number of Participants With Treatment-Emergent Anti-Itepekimab Antibodies Response22
PrimaryFormer Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the 52-Week Placebo-Controlled Treatment Period

Exacerbations were recorded by Investigator. Moderate exacerbations were defined as acute worsening of respiratory symptoms that required either systemic corticosteroids (such as intramuscular \[IM\], intravenous \[IV\], or oral) and/or antibiotics. Severe exacerbations were defined as AECOPD that required hospitalization, observation for \>24 hours in an emergency department/urgent care facility, or resulted in death. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of systemic steroids/antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate was total number of moderate or severe exacerbation events divided by total observation duration and was estimated based on negative binomial regression. Events were adjudicated by third party.

Time frame:
Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
Reported as:
Number · exacerbation per participant-year
Former Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the 52-Week Placebo-Controlled Treatment Period
exacerbation per participant-yearFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2W
Former Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the 52-Week Placebo-Controlled Treatment Period0.879 ± 0.7320.770 ± 0.6360.865 ± 0.721
Statistical analysis
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q4W · Negative binomial regression model · p = = 0.2176 · Rate ratio: 0.876 · 95% CI 0.710 to 1.081
  • Former Smoker Cohort: Placebo vs Former Smoker Cohort: Itepekimab 300 mg Q2W · Negative binomial regression model · p = = 0.8781 · Rate ratio: 0.984 · 95% CI 0.803 to 1.206

Adverse events

Collected over AEs:1st dose (Day 1) to 22 weeks (Wks) post last dose who did not enter LTS18133, upto 75 Wks:Former smoker cohort, 74 Wks:Current smoker cohort/Day 1 upto EOT for who entered LTS18133, upto 55 Wks:Former smoker cohort, 54 Wks:Current smoker cohort. Deaths:Day 1 to EOT for who entered LTS18133, upto approximately 55 Wks:Former smoker cohort and 54 Wks:Current smoker cohort; Day 1 upto end of follow-up for death for each participant for those who did not enter LTS18133, upto approximately 237 Wks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Former Smoker Cohort: Placebo9/321 (2.8%)72/321 (22.4%)75/321 (23.4%)
Former Smoker Cohort: Itepekimab 300 mg Q4W11/302 (3.6%)74/302 (24.5%)69/302 (22.8%)
Former Smoker Cohort: Itepekimab 300 mg Q2W10/325 (3.1%)74/325 (22.8%)58/325 (17.8%)
Current Smoker Cohort: Placebo4/139 (2.9%)28/139 (20.1%)44/139 (31.7%)
Current Smoker Cohort: Itepekimab 300 mg Q2W5/142 (3.5%)36/142 (25.4%)35/142 (24.6%)
Most frequent serious events
Showing 10 of 172
Most frequent serious events
EventFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2WCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders28/32129/30232/32512/13917/142
PneumoniaInfections and infestations6/32110/30212/3253/1393/142
Covid-19Infections and infestations1/3211/3027/3250/1391/142
Covid-19 PneumoniaInfections and infestations0/3210/3021/3252/1392/142
Angina UnstableCardiac disorders0/3211/3020/3252/1390/142
Cerebrovascular AccidentNervous system disorders0/3211/3020/3251/1392/142
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders2/3211/3021/3250/1392/142
Chest PainGeneral disorders1/3210/3020/3250/1392/142
Infective Exacerbation Of Chronic Obstructive Airways DiseaseInfections and infestations4/3211/3021/3251/1391/142
Cardiac Failure CongestiveCardiac disorders0/3211/3024/3250/1390/142
Most frequent other events
Most frequent other events
EventFormer Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2WCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2W
NasopharyngitisInfections and infestations36/32123/30225/32511/1395/142
Covid-19Infections and infestations18/32117/30214/32510/13914/142
FallInjury, poisoning and procedural complications9/3217/3027/3258/1396/142
HypertensionVascular disorders14/32110/3024/3257/1398/142
HeadacheNervous system disorders11/32116/30210/3254/1395/142
RhinitisInfections and infestations2/3212/3022/3257/1394/142
Viral Upper Respiratory Tract InfectionInfections and infestations5/3215/3027/3257/1394/142

Baseline characteristics

The randomized population included all participants with a treatment kit number allocated and recorded in the interactive response technology database, and regardless of whether the treatment kit was used or not.

Age, Continuous
Age, Continuous(years)Former Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2WCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2WTotal
Mean67.7 ± 7.367.7 ± 8.067.9 ± 7.763.7 ± 7.364.7 ± 7.467.0 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Former Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2WCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2WTotal
Female1241251225458483
Male2001782048584751
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Former Smoker Cohort: PlaceboFormer Smoker Cohort: Itepekimab 300 mg Q4WFormer Smoker Cohort: Itepekimab 300 mg Q2WCurrent Smoker Cohort: PlaceboCurrent Smoker Cohort: Itepekimab 300 mg Q2WTotal
American Indian or Alaska Native8651222
Asian30323676111
Native Hawaiian or Other Pacific Islander100001
Black or African American81070025
White2702512701301301051
More than one race213039
Unknown or Not Reported5351115
08

Study locations

238 sites
  • Synexus Phoenix Central (Central Phoenix Medical Clinic)- Site Number : 8400333
    Phoenix, Arizona 85020, United States
  • UCSF Fresno - Site Number : 8400030
    Fresno, California 93701, United States
  • Palmtree Clinical Research Site Number : 8400184
    Palm Springs, California 92262, United States
  • Allianz Research Institute Colorado Site Number : 8400061
    Denver, Colorado 80219, United States
  • Helix Biomedics, LLC - Site Number : 8400049
    Boynton Beach, Florida 33435, United States
  • Innovative Research of West Florida, Inc- Site Number : 8400041
    Clearwater, Florida 33756, United States
  • Beautiful Minds Clinical Research Center Site Number : 8400352
    Cutler Bay, Florida 33157, United States
  • Omega Research - Site Number : 8400031
    DeBary, Florida 32713, United States
  • Sciences Connections, LLC Site Number : 8400045
    Doral, Florida 33178, United States
  • North Florida/South Georgia Veterans Health System Site Number : 8400176
    Gainesville, Florida 32608, United States
  • Finlay Medical Research- Site Number : 8400011
    Greenacres City, Florida 33467, United States
  • Direct Helpers Medical Center Inc- Site Number : 8400065
    Hialeah, Florida 33012, United States
  • Multi-Specialty Research Associates, Inc- Site Number : 8400044
    Lake City, Florida 32055, United States
  • Advanced Pulmonary Research Institute Site Number : 8400018
    Loxahatchee Groves, Florida 33470, United States
  • Columbus Clinical Services- Site Number : 8400054
    Miami, Florida 33125, United States
  • Finlay Medical Research Site Number : 8400007
    Miami, Florida 33126, United States
  • MCR Research Site Number : 8400425
    Miami, Florida 33126, United States
  • Y and L Advance Health Care, Inc D/B/A Elite Clinical Res- Site Number : 8400009
    Miami, Florida 33144, United States
  • My Community Research Center Site Number : 8400060
    Miami, Florida 33155, United States
  • Phoenix Medical Research- Site Number : 8400019
    Miami, Florida 33165, United States
  • Renstar Medical Research- Site Number : 8400015
    Ocala, Florida 34470, United States
  • Central Florida Pulmonary Group, PA- Site Number : 8400192
    Orlando, Florida 32803, United States
  • Oviedo Medical Research Site Number : 8400026
    Oviedo, Florida 32765, United States
  • Innovation Medical Research Center- Site Number : 8400067
    Palmetto Bay, Florida 33157, United States
  • Pines Care Research Center LLC- Site Number : 8400056
    Pembroke Pines, Florida 33025, United States
  • Sarasota Memorial Health Care System Clinical ResearchCenter- Site Number : 8400178
    Sarasota, Florida 34239, United States
  • Genesis Clinical Research, LLC Site Number : 8400182
    Tampa, Florida 33603, United States
  • Clinical Research of West Florida, Inc- Site Number : 8400008
    Tampa, Florida 33606, United States
  • Medster Research, LLC Site Number : 8400051
    Valdosta, Georgia 31605, United States
  • North Georgia Clinical Research Site Number : 8400013
    Woodstock, Georgia 30189, United States
  • Care Access Fairview Heights Site Number : 8400033
    Fairview Heights, Illinois 62208, United States
  • Captain James A. Lovell Federal Health Care Center Site Number : 8400032
    North Chicago, Illinois 60064, United States
  • Illinois Lung Institute- Site Number : 8400024
    Peoria, Illinois 61605, United States
  • The Iowa Clinic Site Number : 8400034
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Garfield- Site Number : 8400063
    Topeka, Kansas 66606, United States
  • Pulmonary & Critical Care Site Number : 8400047
    Shreveport, Louisiana 71105, United States
  • Johns Hopkins Asthma and Allergy Center- Site Number : 8400055
    Baltimore, Maryland 21224, United States
  • Care Access Site Number : 8400276
    Boston, Massachusetts 02110, United States
  • Care Access Site Number : 8400281
    Boston, Massachusetts 02110, United States
  • Revive Research Institute Site Number : 8400186
    Lathrup Village, Michigan 48076, United States
  • Washington University School of Medicine- Site Number : 8400035
    St Louis, Missouri 63110, United States
  • Smart Medical Research Site Number : 8400191
    Brooklyn, New York 11230, United States
  • VA Western New York Healthcare System Site Number : 8400050
    Buffalo, New York 14215, United States
  • New York - Presbyterian Queens- Site Number : 8400028
    Flushing, New York 11355, United States
  • Schenectady Pulmonary and Critical Care Associates- Site Number : 8400029
    Schenectady, New York 12308, United States
  • Advanced Respiratory and Sleep Medicine- Site Number : 8400022
    Huntersville, North Carolina 28078, United States
  • University of Cincinnati- Site Number : 8400042
    Cincinnati, Ohio 45267, United States
  • Toledo Institute of Clinical Research- Site Number : 8400014
    Toledo, Ohio 43617, United States
  • St. Luke's University Health Network- Site Number : 8400187
    Bethlehem, Pennsylvania 18015, United States
  • Temple University Hospital Site Number : 8400062
    Philadelphia, Pennsylvania 19140-5103, United States
  • Allegheny Health Network- Site Number : 8400058
    Pittsburgh, Pennsylvania 15212, United States
  • Lowcountry Lung & Critical Care- Site Number : 8400175
    Charleston, South Carolina 29406, United States
  • Medtrial, LLC Site Number : 8400048
    Columbia, South Carolina 29204, United States
  • TTS Research- Site Number : 8400012
    Boerne, Texas 78006, United States
  • United Memorial Medical Center (UMMC)- Site Number : 8400193
    Houston, Texas 77091, United States
  • Radiance Clinical Research- Site Number : 8400037
    Lampasas, Texas 76550-1820, United States
  • Sun Research Institute - Site Number : 8400183
    San Antonio, Texas 78215, United States
  • AES Salt Lake City- Site Number : 8400332
    Murray, Utah 84123, United States
  • The Rheumatology and Pulmonary Clinic- Site Number : 8400053
    Beckley, West Virginia 25801, United States
  • Investigational Site Number : 0320009
    Berazategui, Buenos Aires CP 1884, Argentina
  • Investigational Site Number : 0320008
    CABA, Buenos Aires C1023AAB, Argentina
  • Investigational Site Number : 0320001
    CABA, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number : 0320005
    Pergamino, Buenos Aires B2700CPM, Argentina
  • Investigational Site Number : 0320006
    Buenos Aires, Buenos Aires F.D. 1060, Argentina
  • Investigational Site Number : 0320002
    Vicente Lopez, Buenos Aires F.D. B1602DQD, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320003
    Rosario, Santa Fe Province S2000DBS, Argentina
  • Investigational Site Number : 0320004
    Rosario, Santa Fe Province S2000JKR, Argentina
  • CEDOES - Centro de Diagnostico e Pesquisa de Osteoporose do ES- Site Number : 0760009
    Vitória, Espírito Santo 29055 450, Brazil
  • SER da Bahia- Site Number : 0760020
    Salvador, Estado de Bahia 40150-150, Brazil
  • CECAP - Centro de Cardiologia Clinica e Pesquisa Dra. Juliana Souza- Site Number : 0760018
    Brasília, Federal District 70710-100, Brazil
  • Hospital Sao Domingos- Site Number : 0760016
    São Luís, Maranhão 65060-645, Brazil
  • Santa Casa de Belo Horizonte - Hospital Emygdio Germano- Site Number : 0760014
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760012
    Curitiba, Paraná 80060-240, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Instituto Ceos Site Number : 0760021
    Porto Alegre, Rio Grande do Sul 90480-020, Brazil
  • Hospital Sao Lucas da PUCRS- Site Number : 0760007
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital Nossa Senhora da Conceicao - Grupo Hospitalar Conceicao- Site Number : 0760006
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Faculdade de Medicina da Universidade Estadual Paulista- Site Number : 0760005
    Botucatu, São Paulo 18618-687, Brazil
  • PUC Campinas - Sociedade Campineira de Educaçao e Instruçao- Site Number : 0760010
    Campinas, São Paulo 13059-900, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clinicos- Site Number : 0760015
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Nucleo de Pesquisa Clinica e Ensino da Rede Sao Camilo- Site Number : 0760013
    São Paulo, São Paulo 04014-002, Brazil
  • Clinica de Alergia Martti Antila Site Number : 0760008
    Sorocaba, São Paulo 18040-425, Brazil
  • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A Site Number : 0760017
    Rio de Janeiro, 20241-180, Brazil
  • Investigational Site Number : 1000008
    Blagoevgrad, 2700, Bulgaria
  • Investigational Site Number : 1000013
    Dupnitsa, 2600, Bulgaria
  • Investigational Site Number : 1000004
    Gabrovo, 5300, Bulgaria
  • Investigational Site Number : 1000009
    Haskovo, 6305, Bulgaria
  • Investigational Site Number : 1000005
    Montana, 3403, Bulgaria
  • Investigational Site Number : 1000002
    Plovdiv, 4002, Bulgaria
  • Investigational Site Number : 1000012
    Rousse, 7000, Bulgaria
  • Investigational Site Number : 1000003
    Rousse, 7002, Bulgaria
  • Investigational Site Number : 1000001
    Sofia, 1142, Bulgaria
  • Investigational Site Number : 1000006
    Sofia, 1680, Bulgaria
  • Investigational Site Number : 1240014
    Kelowna, British Columbia V1Y 4N7, Canada
  • Investigational Site Number : 1240016
    Penticton, British Columbia V2A 5L5, Canada
  • Investigational Site Number : 1240012
    Moncton, New Brunswick E1C2Z3, Canada
  • Investigational Site Number : 1240021
    Ajax, Ontario L1S 2J5, Canada
  • Investigational Site Number : 1240020
    Burlington, Ontario L7N 3V2, Canada
  • Investigational Site Number : 1240022
    Windsor, Ontario N8X 1T3, Canada

Showing the first 100 of 238 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2025, 50 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion. A results delay was requested in Apr 2026.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 50 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 12, 2021
StartActual
Feb 12, 2021
Primary completionActual
Apr 21, 2025
CompletionActual
Aug 28, 2025
Results delay requested
Apr 9, 2026
Results first posted
Oct 9, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 9, 2026
Sites
59 sites removed; no longer in Russia
Show 59 removed
  • Heuer M.D. Research Site Number : 8400016 · Orlando, United States
  • Lexington VA Health Care System- Site Number : 8400036 · Lexington, United States
  • Henry Ford Hospital Site Number : 8400052 · Detroit, United States
  • Sierra Clinical Research- Site Number : 8400005 · Las Vegas, United States
  • American Health Research- Site Number : 8400002 · Charlotte, United States
  • Remington-Davis Inc- Site Number : 8400004 · Columbus, United States
  • OK Clinical Research LLC- Site Number : 8400001 · Edmond, United States
  • Kaiser Permanente Center for Health Research Site Number : 8400039 · Portland, United States
  • VitaLink Research- Gaffney- Site Number : 8400003 · Gaffney, United States
  • Clinical Trials Center of Middle Tennessee Site Number : 8400025 · Franklin, United States
  • Clincove: Plano Primary Care Clinic Site Number : 8400424 · Plano, United States
  • Aurora BayCare Medical Center Site Number : 8400046 · Green Bay, United States
  • CEPIC - Centro Paulista de Investigação Clínica- Site Number : 0760004 · São Paulo, Brazil
  • Investigational Site Number : 1240006 · Sherwood Park, Canada
  • Investigational Site Number : 1240023 · Guelph, Canada
  • Investigational Site Number : 1240009 · Toronto, Canada
  • Investigational Site Number : 1240004 · Sherbrooke, Canada
  • Investigational Site Number : 1240005 · St-charles Borrommee, Canada
  • Investigational Site Number : 1240001 · Trois-Rivières, Canada
  • Investigational Site Number : 1240002 · Victoriaville, Canada
  • Investigational Site Number : 1240003 · Québec, Canada
  • Investigational Site Number : 2760006 · Bendorf, Germany
  • Investigational Site Number : 2760004 · Berlin, Germany
  • Investigational Site Number : 2760005 · Frankfurt am Main, Germany
  • Investigational Site Number : 2760002 · Hamburg, Germany
  • Investigational Site Number : 2760014 · Hanover, Germany
  • Investigational Site Number : 2760007 · Leipzig, Germany
  • Investigational Site Number : 2760003 · Lübeck, Germany
  • Investigational Site Number : 2760001 · Mainz, Germany
  • Investigational Site Number : 2760012 · Neu-Isenburg, Germany
  • …and 29 more on the registry record
Oct 9, 2026
Enrollment
1239→1234
Oct 9, 2026
Eligibility
8 inclusion criteria edited; 5 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedFor former smokers: participants who reportreported that they arewere not currently smoking and smoking cessation must havehad occurred ≥6 months prior to Screening (Visit 1A) with an intention to quit permanently.
  • EditedFor current smokers: participants who reportreported that they arewere currently smoking tobacco (participant smoked at least 1 cigarette per day on average during the past 7 days) at Screening (Visit 1A) and who arewere not currently participating in or planning to initiate a smoking cessation intervention at Screening (Visit 1A) or during Screening period.
  • EditedParticipant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year prior to Screening in a participant in whom other causes of chronic cough [eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis] hashad been excluded).
  • EditedDocumented history of high exacerbation risk defined as having had ≥2 moderate or ≥1 severe exacerbations within the year prior to Screening (Visit 1A), with at least 1 exacerbation treated with systemic corticosteroids. At least one exacerbation must havehad occurred while participants were on their current controller therapy:
  • EditedModerate exacerbations willwould be recorded by the Investigator and arewere defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics.
  • EditedSevere exacerbations willwould be recorded by the Investigator and arewere defined as AECOPD that requirerequired hospitalization or observation for >24 hours in emergency department/urgent care facility.
  • EditedFemale participant iswas not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Editeda WOCBP who agreesagreed to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention. -
Exclusion criteria
  • EditedClinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening (Visit 1A) that maymight affect the participant's participation in the study.
  • EditedParticipants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who arewere at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1A).
  • EditedSuspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in contact with known exposure to COVID-19 at Screening (Visit 1A); known history of COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to Screening (Visit 1A); participants who have had a COVID-19 infection prior Screening (Visit 1A) who havehad not yet sufficiently recovered to participate in the procedures of a clinical trial.
  • EditedEvidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4 weeks before Screening (Visit 1A), significant viral infections within 4 weeks before Screening (Visit 1A) that maymight not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment).
  • EditedThe above information iswas not intended to contain all considerations relevant to a patientparticipant's potential participation in a clinical trial.
Oct 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFormer Smoker Cohort: Annualized rateRate of moderateAdjudicated Moderate or severe acute exacerbationSevere Acute Exacerbation of COPDChronic Obstructive Pulmonary Disease (AECOPD) in former smokersEvents Over the 52-Week Placebo-Controlled Treatment PeriodTime frame: Baseline up to End Of Treatment (EOT) (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) → Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
Oct 9, 2026
Documents
Secondary outcomes
9 edited, 14 added, 7 removed, 5 more
What changed in the outcomes
  • EditedFormer Smoker Cohort: Change from baselineFrom Baseline in prePre-bronchodilator (BD) forced expiratory volumeBronchodilator Forced Expiratory Volume in 1 second (FEV1) in former smokersOne Second at Week 24Time frame: Baseline to Week 24 → Baseline (Day 1) to Week 24
  • EditedFormer Smoker Cohort: Change from baselineFrom Baseline in Evaluating Respiratory Symptoms in COPDChronic Obstructive Pulmonary Disease (E-RS:COPD) total score in former smokersTotal Score at Week 24Time frame: Baseline to Week 24 and Week 52 → Baseline (Day 1) to Week 24
  • EditedFormer Smoker Cohort: Change from baselineFrom Baseline in St. George's Respiratory Questionnaire (SGRQ) total score in former smokersTotal Score at Week 24Time frame: Baseline to Week 24 and Week 52 → Baseline (Day 1) to Week 24
  • EditedProportionFormer Smoker Cohort: Percentage of participants withParticipants With a decrease from baselineDecrease of at leastLeast 4 pointsPoints From Baseline in SGRQ total score in former smokersSt. George's Respiratory Questionnaire Total Score at Week 24Time frame: Baseline to Week 24 and Week 52 → Baseline (Day 1) and Week 24
  • EditedIncidenceFormer Smoker Cohort: Number of treatmentParticipants With Treatment-emergent adverse eventsEmergent Adverse Events (TEAEs), adverse eventTreatment-Emergent Serious Adverse Events (TESAEs), TE Adverse Events of special interestsSpecial Interest (AESIsTEAESIs), serious adverse events (SAEs), and adverse events (AEs) leadingTEAEs Leading to permanent treatment discontinuation in former smokersPermanent Treatment DiscontinuationTime frame: Baseline up to End-of-Study (EOS) (Up to Week 72 for participants not transitioning to the extension study LTS18133; Up to Week 52 for participants transitioning to the extension study LTS18133) → 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)
  • EditedFormer Smoker Cohort: Functional itepekimab concentrationsItepekimab Concentrations in serum in former smokersSerumTime frame: Baseline up to EOS (Up to Week 72 for participants not transitioning to the extension study LTS18133; Up to Week 52 for participants transitioning to the extension study LTS18133) → Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (End of study [EOS]) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)
  • EditedIncidenceFormer Smoker Cohort: Number of treatmentParticipants With Treatment-emergent antiEmergent Anti-itepekimab antibodies responses in former smokersItepekimab Antibodies ResponseTime frame: Baseline up to EOS (Up to Week 72 for participants not transitioning to the extension study LTS18133; Up to Week 52 for participants transitioning to the extension study LTS18133) → 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)
  • EditedCurrent Smoker Cohort: Functional itepekimab concentrationsItepekimab Concentrations in serum in current smokersSerumTime frame: Baseline up to EOS (Week 72 for participants not transitioning to the extension study LTS18133; Week 52 for participants transitioning to the extension study LTS18133) → Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (EOS) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)
  • EditedIncidenceCurrent Smoker Cohort: Number of treatmentParticipants With Treatment-emergent antiEmergent Anti-itepekimab antibodies responses in current smokersItepekimab Antibodies ResponseTime frame: Baseline up to EOS (Week 72 for participants not transitioning to the extension study LTS18133; Week 52 for participants transitioning to the extension study LTS18133) → 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)
  • AddedFormer Smoker Cohort: Annualized Rate of Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Planned Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
  • AddedFormer Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 24Time frame: Baseline (Day 1) to Week 24
  • AddedFormer Smoker Cohort: Rate of Change in Post-Bronchodilator Forced Expiratory Volume in One Second From Baseline (Post-Bronchodilator Forced Expiratory Volume in One Second Slope) After Week 4Time frame: Baseline (Day 1) and from Week 8 up to Week 52 for initial randomized participants; Baseline (Day 1) and from Week 8 up to a variable study treatment period (i.e., 24 weeks minimum and 52 weeks maximum) for additional randomized participants
  • AddedFormer Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 52Time frame: Baseline (Day 1) to Week 52
  • AddedFormer Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 52Time frame: Baseline (Day 1) to Week 52
  • AddedFormer Smoker Cohort: Probability of Participants With First Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Weeks 12, 24, 36 and 52
  • AddedFormer Smoker Cohort: Probability of Participants With First Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Weeks 12, 24, 36 and 52
  • AddedFormer Smoker Cohort: Annualized Rate of Corticosteroid-Treated Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
  • AddedFormer Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease Total Score at Week 52Time frame: Baseline (Day 1) to Week 52
  • AddedFormer Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52Time frame: Baseline (Day 1) to Week 52
  • AddedFormer Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52Time frame: Baseline (Day 1) and Week 52
  • AddedCurrent Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over the 52-Week Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52
  • AddedCurrent Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Weeks 24 and 52Time frame: Baseline (Day 1) and Weeks 24 and 52
  • AddedCurrent Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events, Treatment-Emergent Adverse Events of Special Interest and TEAEs Leading to Permanent Treatment DiscontinuationTime frame: 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)
  • RemovedChange from baseline in post-BD FEV1 in former smokersTime frame: Baseline to Week 24 and Week 52
  • RemovedChange from baseline in pre-BD FEV1 in former smokersTime frame: Baseline to Week 52
  • RemovedTime to first moderate or severe AECOPD in former smokersTime frame: Baseline through EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
  • RemovedAnnualized rate of severe AECOPD in former smokersTime frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
  • RemovedTime to first severe AECOPD in former smokersTime frame: Baseline through EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
  • RemovedAnnualized rate of corticosteroid-treated AECOPD in former smokersTime frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
  • RemovedRate of change in post-BD FEV1 (L) from baseline (post-BD FEV1 slope) in former smokersTime frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
  • …and 5 more, on the record history on ClinicalTrials.gov ↗
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Results posted
    59 sites removed; no longer in Russia
    Show 59 removed
    • Heuer M.D. Research Site Number : 8400016 · Orlando, United States
    • Lexington VA Health Care System- Site Number : 8400036 · Lexington, United States
    • Henry Ford Hospital Site Number : 8400052 · Detroit, United States
    • Sierra Clinical Research- Site Number : 8400005 · Las Vegas, United States
    • American Health Research- Site Number : 8400002 · Charlotte, United States
    • Remington-Davis Inc- Site Number : 8400004 · Columbus, United States
    • OK Clinical Research LLC- Site Number : 8400001 · Edmond, United States
    • Kaiser Permanente Center for Health Research Site Number : 8400039 · Portland, United States
    • VitaLink Research- Gaffney- Site Number : 8400003 · Gaffney, United States
    • Clinical Trials Center of Middle Tennessee Site Number : 8400025 · Franklin, United States
    • Clincove: Plano Primary Care Clinic Site Number : 8400424 · Plano, United States
    • Aurora BayCare Medical Center Site Number : 8400046 · Green Bay, United States
    • CEPIC - Centro Paulista de Investigação Clínica- Site Number : 0760004 · São Paulo, Brazil
    • Investigational Site Number : 1240006 · Sherwood Park, Canada
    • Investigational Site Number : 1240023 · Guelph, Canada
    • Investigational Site Number : 1240009 · Toronto, Canada
    • Investigational Site Number : 1240004 · Sherbrooke, Canada
    • Investigational Site Number : 1240005 · St-charles Borrommee, Canada
    • Investigational Site Number : 1240001 · Trois-Rivières, Canada
    • Investigational Site Number : 1240002 · Victoriaville, Canada
    • Investigational Site Number : 1240003 · Québec, Canada
    • Investigational Site Number : 2760006 · Bendorf, Germany
    • Investigational Site Number : 2760004 · Berlin, Germany
    • Investigational Site Number : 2760005 · Frankfurt am Main, Germany
    • Investigational Site Number : 2760002 · Hamburg, Germany
    • Investigational Site Number : 2760014 · Hanover, Germany
    • Investigational Site Number : 2760007 · Leipzig, Germany
    • Investigational Site Number : 2760003 · Lübeck, Germany
    • Investigational Site Number : 2760001 · Mainz, Germany
    • Investigational Site Number : 2760012 · Neu-Isenburg, Germany
    • …and 29 more on the registry record
    Enrollment 1239→1234
    Eligibility 8 inclusion criteria edited; 5 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedFor former smokers: participants who reportreported that they arewere not currently smoking and smoking cessation must havehad occurred ≥6 months prior to Screening (Visit 1A) with an intention to quit permanently.
    • EditedFor current smokers: participants who reportreported that they arewere currently smoking tobacco (participant smoked at least 1 cigarette per day on average during the past 7 days) at Screening (Visit 1A) and who arewere not currently participating in or planning to initiate a smoking cessation intervention at Screening (Visit 1A) or during Screening period.
    • EditedParticipant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year prior to Screening in a participant in whom other causes of chronic cough [eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis] hashad been excluded).
    • EditedDocumented history of high exacerbation risk defined as having had ≥2 moderate or ≥1 severe exacerbations within the year prior to Screening (Visit 1A), with at least 1 exacerbation treated with systemic corticosteroids. At least one exacerbation must havehad occurred while participants were on their current controller therapy:
    • EditedModerate exacerbations willwould be recorded by the Investigator and arewere defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics.
    • EditedSevere exacerbations willwould be recorded by the Investigator and arewere defined as AECOPD that requirerequired hospitalization or observation for >24 hours in emergency department/urgent care facility.
    • EditedFemale participant iswas not pregnant, not breastfeeding, and at least one of the following conditions applies:
    • Editeda WOCBP who agreesagreed to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention. -
    Exclusion criteria
    • EditedClinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening (Visit 1A) that maymight affect the participant's participation in the study.
    • EditedParticipants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who arewere at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1A).
    • EditedSuspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in contact with known exposure to COVID-19 at Screening (Visit 1A); known history of COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to Screening (Visit 1A); participants who have had a COVID-19 infection prior Screening (Visit 1A) who havehad not yet sufficiently recovered to participate in the procedures of a clinical trial.
    • EditedEvidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4 weeks before Screening (Visit 1A), significant viral infections within 4 weeks before Screening (Visit 1A) that maymight not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment).
    • EditedThe above information iswas not intended to contain all considerations relevant to a patientparticipant's potential participation in a clinical trial.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFormer Smoker Cohort: Annualized rateRate of moderateAdjudicated Moderate or severe acute exacerbationSevere Acute Exacerbation of COPDChronic Obstructive Pulmonary Disease (AECOPD) in former smokersEvents Over the 52-Week Placebo-Controlled Treatment PeriodTime frame: Baseline up to End Of Treatment (EOT) (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) → Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
    Secondary outcomes 9 edited, 14 added, 7 removed, 5 more
    What changed in the outcomes
    • EditedFormer Smoker Cohort: Change from baselineFrom Baseline in prePre-bronchodilator (BD) forced expiratory volumeBronchodilator Forced Expiratory Volume in 1 second (FEV1) in former smokersOne Second at Week 24Time frame: Baseline to Week 24 → Baseline (Day 1) to Week 24
    • EditedFormer Smoker Cohort: Change from baselineFrom Baseline in Evaluating Respiratory Symptoms in COPDChronic Obstructive Pulmonary Disease (E-RS:COPD) total score in former smokersTotal Score at Week 24Time frame: Baseline to Week 24 and Week 52 → Baseline (Day 1) to Week 24
    • EditedFormer Smoker Cohort: Change from baselineFrom Baseline in St. George's Respiratory Questionnaire (SGRQ) total score in former smokersTotal Score at Week 24Time frame: Baseline to Week 24 and Week 52 → Baseline (Day 1) to Week 24
    • EditedProportionFormer Smoker Cohort: Percentage of participants withParticipants With a decrease from baselineDecrease of at leastLeast 4 pointsPoints From Baseline in SGRQ total score in former smokersSt. George's Respiratory Questionnaire Total Score at Week 24Time frame: Baseline to Week 24 and Week 52 → Baseline (Day 1) and Week 24
    • EditedIncidenceFormer Smoker Cohort: Number of treatmentParticipants With Treatment-emergent adverse eventsEmergent Adverse Events (TEAEs), adverse eventTreatment-Emergent Serious Adverse Events (TESAEs), TE Adverse Events of special interestsSpecial Interest (AESIsTEAESIs), serious adverse events (SAEs), and adverse events (AEs) leadingTEAEs Leading to permanent treatment discontinuation in former smokersPermanent Treatment DiscontinuationTime frame: Baseline up to End-of-Study (EOS) (Up to Week 72 for participants not transitioning to the extension study LTS18133; Up to Week 52 for participants transitioning to the extension study LTS18133) → 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)
    • EditedFormer Smoker Cohort: Functional itepekimab concentrationsItepekimab Concentrations in serum in former smokersSerumTime frame: Baseline up to EOS (Up to Week 72 for participants not transitioning to the extension study LTS18133; Up to Week 52 for participants transitioning to the extension study LTS18133) → Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (End of study [EOS]) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)
    • EditedIncidenceFormer Smoker Cohort: Number of treatmentParticipants With Treatment-emergent antiEmergent Anti-itepekimab antibodies responses in former smokersItepekimab Antibodies ResponseTime frame: Baseline up to EOS (Up to Week 72 for participants not transitioning to the extension study LTS18133; Up to Week 52 for participants transitioning to the extension study LTS18133) → 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 75 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 55 weeks)
    • EditedCurrent Smoker Cohort: Functional itepekimab concentrationsItepekimab Concentrations in serum in current smokersSerumTime frame: Baseline up to EOS (Week 72 for participants not transitioning to the extension study LTS18133; Week 52 for participants transitioning to the extension study LTS18133) → Baseline (Day 1), Weeks 2, 4, 8, 12, 24, 36, 52 (EOT), 58 and 72 (EOS) (Weeks 58 and 72 applicable for participants not transitioning to the LTS18133 study)
    • EditedIncidenceCurrent Smoker Cohort: Number of treatmentParticipants With Treatment-emergent antiEmergent Anti-itepekimab antibodies responses in current smokersItepekimab Antibodies ResponseTime frame: Baseline up to EOS (Week 72 for participants not transitioning to the extension study LTS18133; Week 52 for participants transitioning to the extension study LTS18133) → 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)
    • AddedFormer Smoker Cohort: Annualized Rate of Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Planned Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
    • AddedFormer Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 24Time frame: Baseline (Day 1) to Week 24
    • AddedFormer Smoker Cohort: Rate of Change in Post-Bronchodilator Forced Expiratory Volume in One Second From Baseline (Post-Bronchodilator Forced Expiratory Volume in One Second Slope) After Week 4Time frame: Baseline (Day 1) and from Week 8 up to Week 52 for initial randomized participants; Baseline (Day 1) and from Week 8 up to a variable study treatment period (i.e., 24 weeks minimum and 52 weeks maximum) for additional randomized participants
    • AddedFormer Smoker Cohort: Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second at Week 52Time frame: Baseline (Day 1) to Week 52
    • AddedFormer Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Week 52Time frame: Baseline (Day 1) to Week 52
    • AddedFormer Smoker Cohort: Probability of Participants With First Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Weeks 12, 24, 36 and 52
    • AddedFormer Smoker Cohort: Probability of Participants With First Adjudicated Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Weeks 12, 24, 36 and 52 Over the Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Weeks 12, 24, 36 and 52
    • AddedFormer Smoker Cohort: Annualized Rate of Corticosteroid-Treated Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
    • AddedFormer Smoker Cohort: Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease Total Score at Week 52Time frame: Baseline (Day 1) to Week 52
    • AddedFormer Smoker Cohort: Change From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52Time frame: Baseline (Day 1) to Week 52
    • AddedFormer Smoker Cohort: Percentage of Participants With a Decrease of at Least 4 Points From Baseline in St. George's Respiratory Questionnaire Total Score at Week 52Time frame: Baseline (Day 1) and Week 52
    • AddedCurrent Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease Events Over the 52-Week Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52
    • AddedCurrent Smoker Cohort: Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second at Weeks 24 and 52Time frame: Baseline (Day 1) and Weeks 24 and 52
    • AddedCurrent Smoker Cohort: Number of Participants With Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events, Treatment-Emergent Adverse Events of Special Interest and TEAEs Leading to Permanent Treatment DiscontinuationTime frame: 1st dose (Day 1) up to 22 weeks post last dose (considering maximum treatment exposure) for who did not enter LTS18133 (approximately 74 weeks); up to EOT (considering maximum treatment exposure) for who entered LTS18133 (approximately 54 weeks)
    • RemovedChange from baseline in post-BD FEV1 in former smokersTime frame: Baseline to Week 24 and Week 52
    • RemovedChange from baseline in pre-BD FEV1 in former smokersTime frame: Baseline to Week 52
    • RemovedTime to first moderate or severe AECOPD in former smokersTime frame: Baseline through EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
    • RemovedAnnualized rate of severe AECOPD in former smokersTime frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
    • RemovedTime to first severe AECOPD in former smokersTime frame: Baseline through EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
    • RemovedAnnualized rate of corticosteroid-treated AECOPD in former smokersTime frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
    • RemovedRate of change in post-BD FEV1 (L) from baseline (post-BD FEV1 slope) in former smokersTime frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants)
    • …and 5 more, on the record history on ClinicalTrials.gov ↗
    + 5 other changes: index terms, verification date, registry dates, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04751487
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Feb 12, 2021
Primary completion
Apr 21, 2025
Completion
Aug 28, 2025
Results posted
Oct 9, 2026
Last update
Oct 9, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion